Connect your AI

Ultragenyx Pharmaceutical RARE PP&E (Net)

PP&E (Net) at other companies

Eli LillyLLY

$26.54B+43.7%

AmgenAMGN

$8.22B+23.0%

Ionis PharmaceuticalsIONS

$142.4M+38.4%

Arrowhead ResearchARWR

$374.82M-2.6%

CRISPR TherapeuticsCRSP

$112.18M-13.3%

ModernaMRNA

$2.09B-5.7%

Other financials

Income statement

Revenue$136.0M-2.2%

Operating income-$169.0M-18.2%

Net income-$185.0M-22.5%

EPS (diluted)-$1.84-17.2%

Balance sheet

Cash & equivalents$175.0M+37.8%

Total debt$36.0M-10.8%

Total equity-$236.0M-264%

Total assets$1.3B-1.2%

Cash flow

Operating cash flow-$197.0M-18.7%

CapEx$1.0M0.0%

Free cash flow-$198.0M-18.6%

Valuation

Market cap$2.83B-39.4%

P/S4.2×-3.7×

Profitability

Gross margin97.2%—

Operating margin-83.8%-3.0pp

Net margin-90.9%-2.1pp

FCF margin-75.1%+10.7pp

Returns & leverage

Return on equity-325.6%+36.9pp

Debt / equity3.7×—

Current ratio2×-0.4×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Ultragenyx Pharmaceutical's PP&E (net)?: Ultragenyx Pharmaceutical (RARE) reported PP&E (net) of $239M in Q1 2026.
How has Ultragenyx Pharmaceutical's PP&E (net) changed year-over-year?: Ultragenyx Pharmaceutical's PP&E (net) decreased by 8.4% year-over-year, from $260.91M to $239M.
What is the long-term trend for Ultragenyx Pharmaceutical's PP&E (net)?: Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's PP&E (net) has grown at a 27.1% compound annual growth rate (CAGR), from $73.52M to $244M.
What does PP&E (net) mean?: Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.